SECTION

#Clinical Trial

Total 2 related articles

Live wire →

NewsTag

Featured

AC Immune H1 Results: Alzheimer's Vaccine Data on the Horizon, Cash Runway Secured Through 2027

Lead report

美股

Lead report

AC Immune H1 Results: Alzheimer's Vaccine Data on the Horizon, Cash Runway Secured Through 2027

AC Immune reported H1 2025 results with increased R&D spending and a cash runway into 2027. Key catalyst is the upcoming Phase IIb data for ACI-24.060, with partnerships with Roche and Lilly advancing.

YayaNews2026-08-05 19:473 min

来源: Seeking Alpha

美股

Summit Therapeutics Announces FDA PDUFA Date for Ivonescimab and HARMONi-3 Data Timeline

Summit Therapeutics sets FDA PDUFA target date for ivonescimab on November 14 and plans HARMONi-3 PFS data readout in H2 2026. Analysis of regulatory decisions and clinical progress impacts on stock and industry landscape.

YayaNews2026-07-24 11:163 min来源: Seeking Alpha

Summit Therapeutics Announces FDA PDUFA Date for Ivonescimab and HARMONi-3 Data Timeline

Featured

AC Immune H1 Results: Alzheimer's Vaccine Data on the Horizon, Cash Runway Secured Through 2027

Summit Therapeutics Announces FDA PDUFA Date for Ivonescimab and HARMONi-3 Data Timeline

More Related Articles